Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Image-Guided Cryoablation Could Improve Effectiveness of Cancer Immunotherapy

XTALKS VITALS NEWS

Immunotherapy

According to Williams, the technique could improve effectiveness and reduce costs of pricey new cancer therapies.

Tweetables from this article:

Tweet: The average #immunotherapy costs $300,000 per year http://ctt.ec/hY2fH+ The average #immunotherapy costs $300,000 per year.

Share this!

October 14, 2016 | by Sarah Hand, M.Sc.

Dr. Jason Williams, a medical doctor with Image Guided Cancer Specialist, has developed a method of delivering immunotherapy cancer drugs directly into tumors using image-guided cryoablation. According to Williams, the technique could improve effectiveness and reduce costs of pricey new cancer therapies.

Historically, cancer has been a tough disease to treat as tumor cells use multiple mechanisms to evade the body’s immune system. New immunotherapy drugs – such as Bristol-Myers Squibb’s Yervoy and Opdivo, and Merck’s Keytruda – trigger the immune system to mount a response against cancerous tissue.

Unfortunately, these drugs are very expensive, with the average cost totaling $300,000 per year. In addition, these drugs have the propensity to over-activate the immune system, leading to a potentially life-threatening condition known as a cytokine storm.

This reaction is made more likely because the immunotherapy drugs are administered to patients intravenously. Williams argues that targeting drug delivery directly to the site of the tumor could improve outcomes and mitigate the risk of serious autoimmune adverse events.



Williams’ views are supported by research; in animal studies, injection of immunotherapy drugs coupled with cryoablation of tumors has resulted in an 80 percent improvement in survival rates. Cryoablation kills tumor cells by stimulating the release of anti-cancer antigens, however this treatment is often insufficient if used in isolation.

“Biologically, the idea makes sense, because intentionally leaving dead tissue for the body to dispose of naturally is a way to potentially immunize against cancer cells,” said Dr. Alex Y. Huang, associate professor of the department of pediatrics at Case Western Reserve University School of Medicine, and clinical fellowship director of the division of pediatric hematology/oncology at University Hospitals Case Medical Center/Rainbow Babies & Children's Hospital. “Cryoablation uses cold temperature to induce necrotic cell death, which is a signal for the immune system to wake up. The dead tumor proteins will be seen as foreign by the immune system, which will attack the cancer.”

Williams’s method begins by applying cryoablation to tumors to freeze and kill cancer cells. Using image-guidance technology, probes are inserted into the tumor and immunotherapy drugs – namely immune checkpoint inhibitors – are injected directly into the cancerous mass.

“This has the double benefit of activating the local immune system against cancer in other locations, without globally activating the immune system against the patient's healthy tissue,” said Huang. “The risk of hitting the wrong tissue is low, and we know these drugs are safe at much higher systemic rather than smaller, targeted doses. The potential for systemic toxicity is lower and, because the drugs are given only locally, the cost is vastly reduced.”

A localized injection reduces the amount of immunotherapy drug needed to stimulate a patient response; animal models typically require one-eighth the dose used for intravenous drug delivery. This means that local injection of currently-approved therapies could cost $37,500 – as opposed to $300,000 – per year.

Williams has tested this method in 80 human cancer patients. One patient, a woman with advanced breast cancer that had metastasized to her lungs, bones and brain – saw a particularly positive outcome.

“A single treatment ablated two lung tumors and, using combination immunotherapy, she had complete resolution of the tumors in the body and 50% reduction in size and number of the brain tumors,” said Williams. “In many patients, we have seen complete resolution of their cancer, even in remote sites not directly treated. We have treated enough patients now to know that these results are not a fluke, but I look forward to testing this therapy in an official clinical trial.”


Keywords: Cancer, Immunotherapy, Drug Delivery


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News


Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News


IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.